Genencor scales back health care activities
The decision results in an immediate reduction in force in Genencor affecting 22 positions and leaving 31 positions in the health care business. To ensure and support a divestment, focus will mainly be on the sections of the project portfolio that carry sales potential. This process is expected to be finalised in the months ahead.
During the transition period, Genencor will continue development activities for GCR-8015 (preclinical) and GCR-3888 (clinical), two compounds for hematologic malignancies.
The net restructuring costs involved were included in the previously announced special items for Genencor in 2005/06 totalling approximately DKK 300 million.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.